Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
NASDAQ:SHPH
Top Page
No summary available
Positive Factors
Strategic Management Restructuring
The appointment of a new interim CEO and CSO aims to enhance business focus and capital market engagement, potentially improving strategic execution and financial management.
Negative Factors
Financial Distress
The lack of revenue and ongoing losses highlight financial instability, posing risks to sustainability and necessitating urgent strategic and operational adjustments.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Management Restructuring
The appointment of a new interim CEO and CSO aims to enhance business focus and capital market engagement, potentially improving strategic execution and financial management.
Read all positive factors
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.19M
Dividend YieldN/A
Average Volume (3M)424.69K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue GrowthN/A
EPS Growth79.31%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.25
Shares Outstanding5,591,290
10 Day Avg. Volume561,719
30 Day Avg. Volume424,685
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.31
Enterprise Value/Market Cap0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-669.21
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shuttle Pharmaceuticals Holdings, Inc. Business Overview & Revenue Model
Company Description
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage inclu...
How the Company Makes Money
Shuttle Pharmaceuticals Holdings, Inc. generates revenue primarily through the development and commercialization of its proprietary radiation sensitizer products. The company may also engage in strategic partnerships and collaborations with resear...
Shuttle Pharmaceuticals Holdings, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -5.97K | -60.83K |
| EBITDA | -11.36M | -7.78M | -3.99M | -4.32M | -1.04M |
| Net Income | -11.72M | -9.14M | -6.59M | -5.00M | -1.15M |
Balance Sheet | |||||
| Total Assets | 10.48M | 2.51M | 5.95M | 8.65M | 651.64K |
| Cash, Cash Equivalents and Short-Term Investments | 334.00K | 1.92M | 5.46M | 8.42M | 504.75K |
| Total Debt | 232.15K | 1.17M | 1.09M | 748.30K | 978.88K |
| Total Liabilities | 8.22M | 1.80M | 1.90M | 975.68K | 2.28M |
| Stockholders Equity | 2.25M | 709.15K | 4.06M | 7.68M | -1.63M |
Cash Flow | |||||
| Free Cash Flow | -9.48M | -7.33M | -5.60M | -2.67M | -300.34K |
| Operating Cash Flow | -9.48M | -7.33M | -5.58M | -2.67M | -300.34K |
| Investing Cash Flow | -3.06M | 2.92M | -2.83M | 0.00 | 0.00 |
| Financing Cash Flow | 10.95M | 3.76M | 2.57M | 10.58M | 687.93K |
Shuttle Pharmaceuticals Holdings, Inc. Technical Analysis
Negative
0.75
Price Trends
1.12
Negative
1.46
Negative
2.55
Negative
Market Momentum
-0.11
Negative
41.02
Neutral
54.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHPH, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 1.12, and below the 200-day MA of 2.55, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 41.02 is Neutral, neither overbought nor oversold. The STOCH value of 54.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SHPH.
Shuttle Pharmaceuticals Holdings, Inc. Risk Analysis
Shuttle Pharmaceuticals Holdings, Inc. disclosed 59 risk factors in its most recent earnings report. Shuttle Pharmaceuticals Holdings, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shuttle Pharmaceuticals Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $4.19M | -0.25 | -9999.00% | ― | ― | 79.31% | |
47 Neutral | $4.07M | -0.42 | ― | ― | ― | ― | |
46 Neutral | $1.77M | >-0.01 | 2.66% | ― | -27.81% | ― | |
45 Neutral | $25.12M | ― | -43.00% | ― | -26.92% | 69.90% | |
45 Neutral | $3.96M | -1.90 | -85.94% | ― | 25.02% | 55.11% | |
42 Neutral | $1.98M | -0.43 | ― | ― | ― | ― |
* Healthcare Sector Average
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.75
-9.63
-92.77%
CPHI
China Pharma Holdings
0.62
-0.74
-54.41%
SNOA
Sonoma Pharmaceuticals
2.29
0.21
10.10%
RDHL
RedHill Biopharma
0.80
-1.98
-71.26%
PRFX
PainReform
2.34
-8.41
-78.23%
UPC
Universe Pharmaceuticals
3.15
-0.38
-10.76%
Shuttle Pharmaceuticals Holdings, Inc. Corporate Events
M&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Shuttle Pharmaceuticals Accelerates Equity Payment in Asset Deal
Neutral
Dec 29, 2025
On December 23, 2025, Shuttle Pharmaceuticals Holdings, Inc. amended an existing asset purchase agreement involving its Canadian subsidiary 1563868 B.C. Ltd., Canadian seller 1542770 BC Ltd., and a seller guarantor, accelerating part of the first ...
Executive/Board Changes
Shuttle Pharmaceuticals CFO Resigns, Interim CEO Steps In
Neutral
Nov 28, 2025
On November 21, 2025, Shuttle Pharmaceuticals Holdings, Inc. announced the resignation of Timothy Lorber as Chief Financial Officer. In connection with his resignation, a Separation Agreement was established, allowing Mr. Lorber to provide part-ti...
Business Operations and StrategyM&A Transactions
Shuttle Pharmaceuticals Completes Strategic Asset Acquisition
Positive
Nov 26, 2025
On November 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. finalized an Asset Purchase Agreement with its subsidiary and other parties, acquiring substantial assets and liabilities from a Canadian corporation. The transaction involved a cash pay...
Business Operations and StrategyLegal Proceedings
Shuttle Pharmaceuticals Faces Agreement Termination and Settlement
Negative
Nov 21, 2025
On October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. received a termination notice from Theradex Systems, Inc. regarding their master agreement, leading to a settlement where Shuttle Pharmaceuticals will pay $300,000 to Theradex to settle o...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Shuttle Pharmaceuticals Regains Compliance with Nasdaq
Neutral
Nov 17, 2025
Shuttle Pharmaceuticals Holdings, Inc. reported a stockholders’ equity of $1,394,161 for the quarter ended September 30, 2025, falling short of the Nasdaq’s requirement of $2,500,000. However, the company believes it has regained compl...
Private Placements and FinancingRegulatory Filings and Compliance
Shuttle Pharmaceuticals Raises $2.5 Million in Private Placement
Neutral
Nov 7, 2025
On November 3, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a securities purchase agreement to issue and sell a pre-funded warrant for 625,156 shares of common stock, raising approximately $2.5 million in a private placement. The offe...
Business Operations and StrategyM&A Transactions
Shuttle Pharmaceuticals Acquires Molecule’s Assets for $10M
Negative
Oct 21, 2025
On October 20, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a binding term sheet with 1542770 BC Ltd. to acquire substantially all of Molecule’s assets and liabilities for $10 million, payable in cash and company stock, continge...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―